INHIBITORY EFFECT OF THE TRFK-5 ANTI-IL-5 ANTIBODY IN A GUINEA-PIG MODEL OF ASTHMA

被引:202
|
作者
MAUSER, PJ
PITMAN, A
WITT, A
FERNANDEZ, X
ZURCHER, J
KUNG, T
JONES, H
WATNICK, AS
EGAN, RW
KREUTNER, W
ADAMS, GK
机构
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1993年 / 148卷 / 06期
关键词
D O I
10.1164/ajrccm/148.6_Pt_1.1623
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
To investigate the role of IL-5 in airway hyperreactivity and pulmonary eosinophilia, we used a model of allergic asthma in guinea pigs and a neutralizing monoclonal antibody (TRFK-5) directed against murine IL-5. Sensitized guinea pigs were challenged with 1% ovalbumin (OVA) aerosol and assessed for airway eosinophilia (by bronchoalveolar lavage [BAL] and histologic evaluation of airway tissue) and bronchoconstrictor responsiveness to substance P (SP) (as RL(100) and Cdyn(40)) 24 h later. OVA challenge of sensitized animals caused a significant increase in airway responsiveness to SP, with a 4.9-fold decrease in RL(100) and a 4.7-fold decrease in Cdyn(40). Accompanying this increased sensitivity to SP was a 9-fold increase in eosinophils recovered in BAL and a 4- to 5-fold increase in eosinophils in intrapulmonary bronchial tissue. Intraperitoneal treatment with 10 mg/kg of the IL-5 antibody 2 h before OVA challenge blocked BAL and lung tissue increases in eosinophils but had no effect on the development of airway sensitivity to SP. In contrast, similar treatment with 30 mg/kg of this antibody blocked OVA-induced increased sensitivity to SP as well as BAL and lung tissue eosinophilia. These data suggest a critical and possibly independent role for IL-5 in allergic airway hyperresponsiveness and the accumulation of eosinophils within the lung of the guinea pig.
引用
收藏
页码:1623 / 1627
页数:5
相关论文
共 50 条
  • [31] Anti-IL-5 treatments in severe eosinophilic asthma: real life datas
    Ozdel Ozturk, Betul
    Bavbek, Sevim
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 148 - 159
  • [32] Anti-IL-5 biologics carve out severe-asthma niche
    Elie Dolgin
    Nature Biotechnology, 2014, 32 : 1075 - 1076
  • [33] Anti-IL-5 biologics carve out severe-asthma niche
    Dolgin, Elie
    NATURE BIOTECHNOLOGY, 2014, 32 (11) : 1075 - 1076
  • [34] Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
    Korn, Stephanie
    Ehrhard, Lucas
    Voigt, Stefanie
    Buhl, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [35] Effect of anti-IL-5 (mezolizumab) on airway eosinophils in asthmatics
    Kay, AB
    Flood-Page, PT
    Menzies-Gow, AN
    Robinson, DS
    ALLERGY FRONTIERS AND FUTURES, 2003, : 298 - 301
  • [36] Anti-IL-5 treatments are a useful adjunct for treatment of chronic severe asthma
    Nixon, Gillian M.
    McNamara, David G.
    Armstrong, David S.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2024, 60 (10) : 613 - 615
  • [37] A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma
    Busse, William W.
    Ring, Johannes
    Huss-Marp, Johannes
    Kahn, Jean-Emmanuel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (04) : 803 - 813
  • [38] Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma
    Ozyigit, Leyla Pur
    Ozturk, Ayse Bilge
    Bavhek, Sevim
    TURKISH THORACIC JOURNAL, 2020, 21 (01): : 61 - 68
  • [39] Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma
    Pavord, Ian
    Korn, Stephanie
    Howarth, Peter
    Bleecker, Eugene
    Buhl, Roland
    Keene, Oliver
    Ortega, Hector
    Pascal, Pascal Chanez
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [40] Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma
    Eger, Katrien
    Pet, Lodewijk
    Weersink, Els J. M.
    Bel, Elisabeth H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (07): : 2913 - 2915